Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

se of $3,000. Higher legal, audit and consulting fees in the first quarter of fiscal 2009 were offset by lower wages due to the one time charge of $434,000 relating to the resignation of the Company's Chairman in the first quarter of fiscal 2008.

Amortization of intangible and capital assets

Amortization of intangible assets in the first quarter of fiscal 2009 totaled $3,000 (2008 - $7,000). Amortization of capital assets in the first quarter of fiscal 2009 totaled $64,000 (2008 - $66,000).

Stock-based compensation

Stock-based compensation expense in the first quarter of fiscal 2009 totaled $nil (2008 - $12,000). The stock-based compensation expense in the first quarter of fiscal 2008 relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income

Interest income in the first quarter of fiscal 2009 totaled $205,000 (2008 - $104,000) and is mainly the result of higher cash balances.

Foreign exchange loss

Foreign exchange losses in the first quarter of fiscal 2009 totaled $150,000 (2008 - $108,000). Foreign exchange losses are mainly the result of the foreign currency translation of the Company's integrated foreign operation in Ireland. The net assets in Ireland consist mainly of cash and cash equivalents, denominated in Euro dollars, which are used to fund clinical trials of Topical Interferon Alpha-2b in Europe. In addition, U.S. dollar purchases of inventory for distribution in Canada also contributed to the foreign exchange loss.

Income taxes

Income tax expense in the first quarter of fiscal 2009 totaled $30,000 (2008 - $32,000). All income taxes are attributable to the Company's operations in Ireland.

cash flow

Operating activities

N
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... DUBLIN and PHILADELPHIA , ... the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has filed ... against Anchen Pharmaceuticals,Inc. and Anchen, Inc. (collectively "Anchen") for the infringement ... (the ,794 patent). , , ...
... GENEVA, Switzerland , June 3, 2010 , ... - PEARL I Trial Meets Primary Efficacy and Safety Endpoints , ... - PregLem Preparing for Submission to the European Medicines Agency in,2010 , ... PregLem, the European specialty biopharmaceutical company focused on,women,s reproductive medicine, announces positive Phase III ...
... , June 2 Cellectis (Alternext: ... Paques, PhD, Chief Scientific Officer, Julianne Smith , PhD, ... surgery, and Feng Zhang , PhD, Research Director at ... on meganucleases and genome surgery at the FASEB Summer ...
Cached Biology Technology:INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 2INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 3PregLem Announces Positive Phase III Results for Esmya(TM) 2PregLem Announces Positive Phase III Results for Esmya(TM) 3PregLem Announces Positive Phase III Results for Esmya(TM) 4Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering 2Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering 3
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... sensitive biological experiments is always a delicate affair. ... by Cheryl Nickerson, whose working laboratory aboard the ... miles above the Earth, traveling at some 17,000 ... at Arizona State University,s Biodesign Institute, is using ...
... has gifted the Institute for Genomic Biology (IGB) a ... by the NSF, Ember will be managed by the ... Ember for a while now through the NCSA, mainly ... "It can perform a lot of tasks that our ...
... a deep, dark mystery. That is changing, though, as ... ocean-going creatures. Stanford marine sciences professor and ... technology to enable live feeds of animal movements relayed ... help protect marine ecosystems by revolutionizing how we understand ...
Cached Biology News:International space station plays host to innovative infectious disease research 2International space station plays host to innovative infectious disease research 3International space station plays host to innovative infectious disease research 4International space station plays host to innovative infectious disease research 5International space station plays host to innovative infectious disease research 6New supercomputer to aid genomics research 2Wiring the ocean 2
... (GLYT2). The antiserum has been tested on ... The staining pattern obtained with AB1773 corresponds ... hybridization with probes to GLYT2 mRNA and ... neurons. Preabsorption of the antiserum with the ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. PROTECT ... potent inhibitor of MMP-2 that acts in ... 1.7 μM). Purity: ≥98% by TLC. ... in solution, reconstitute just prior to use. ...
... with an early protein. ... hours post-infection exhibiting an intranuclear ... intensity between 6-24 hours. ... coarsely granular staining. No ...
Biology Products: